Dr. Daniel Q. Bach, MD

Dr. Bach practices at South Pacific Surgery Center in Beverly Hills, California.

Dr. Bach's NPI, 1528407780, was assigned on June 21, 2013. Dr. Bach graduated from Feinberg School of Medicine in 2013. Dr. Bach holds California license 150337.

Dr. Bach's primary practice is South Pacific Surgery Center, at 99 La Cienega Boulevard Suite 102, Beverly Hills, CA 90211. The practice phone is (310) 360-7368.

Dr. Bach's primary practice is South Pacific Surgery Center in Beverly Hills, California. Dr. Bach is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Bach to 1 more group practice or clinic and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bach practices, 4 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Bach's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Bach is licensed in California.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, contact dermatitis, itchy rashes, psoriasis, rash and scalp rash among the conditions Dr. Bach treats.

CMS data shows 1,629 Medicare services from Dr. Bach across 12 procedure codes in 2024, for 371 Medicare patients. Medicare paid $86,203 for them. Every service was in an office.

CMS counts 371 Medicare patients who saw Dr. Bach in 2024. The largest group is 65 to 74, with 181 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bach's median patient age at 56, with 50% women.

In 2024, Dr. Bach wrote 1,438 Medicare Part D claims for 423 patients. 90% of them were for generic drugs. CMS names the drug for 1,234 of them, across 18 drugs with 11 or more claims each, at $215,716 in total drug cost. In 2023, CMS named 1,124 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Bach for performance year 2024, reported as part of a group. Dr. Bach accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bach as offering telehealth. CMS counts 517 procedures of removal of skin lesions by Dr. Bach, more than 87% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 21 papers to Dr. Bach, published from 2012 to 2024. 2020 was the busiest year, with 6. The most frequent topics are Skin Neoplasms, Dermatology and Skin. Dr. Bach has published most often in J Am Acad Dermatol. Dr. Bach's most frequent co-authors are Nolan Maloney, MD, Kyle Cheng, MD and Jason Jinseok Yang, MD.

CMS Open Payments shows 386 general payments to Dr. Bach from 28 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 96% of the total. Abbvie Inc. paid the most, $1,490. It also lists 3 research payments totaling $7,440 in 2023.

Dr. Bach graduated from Feinberg School of Medicine in 2013.